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INTRODUCTION 
 
The most recent World Health Organization (WHO) reports show that there 
were 9.0 million new tuberculosis (TB) cases and 1.5 million tuberculosis (TB) 
deaths. Tb is the leading cause of death from an infectious disease worldwide, next 
to the human immunodeficiency virus (HIV). Co-infection with the HIV fuels the 
global TB crisis, and successful TB treatment is further complicated and hampered 
by the existence of multidrug- resistant (MDR) TB and extensively drug resistant 
(XDR) TB
[1].
 
 
 TUBERCULOSIS is a communicable disease caused by Mycobacterium 
tuberculosis (MTB), a disease that remains as one of the most alarming health 
problems worldwide. It is simply spreadable by sneezing, cough and speaking. 
Predisposing factors for TB include close contact with large populations of people. 
Humans are the only reservoir for the Mycobacterium tuberculosis.     
 
 Bedaquiline received U.S. Food and Drug Administration (FDA) approval in 
late 2011. The safety and effectiveness of these new agents are still uncertain, 
because they are based on the results of relatively small studies 
[2]
. 
 
 
HISTORY : 
 Although Dr. Richard Morton established the pulmonary form associated 
with tubercles as pathology in 1689 due to the variety of its symptoms, TB was not 
identified as a single disease until the 1820s
[3]
. It was not named "tuberculosis" until 
1839, by J. L. Schönlein
[4]
 . The bacillus causing tuberculosis, M. tuberculosis, was 
identified and described on 24 March 1882 by Robert Koch
[8]
.   
 
 Albert Calmette and Camille Guérin achieved the first genuine success in 
immunization against tuberculosis in 1906, using attenuated bovine-strain 
tuberculosis. It was called bacille Calmette–Guérin (BCG). The BCG vaccine was 
first used on humans in 1921 in France, but received widespread acceptance in the 
US, Great Britain, and Germany only after World War II
[8]
. 
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TYPES OF TUBERCULOSIS :  
         Tuberculosis is a contagious disease; it affects almost all the important organs 
of the body. Clinically, tuberculosis is broadly categorized into three major 
categories  
1. Primary tuberculosis: affects a person who had never been exposed to the 
bacterium
[5] 
2. Secondary tuberculosis: the bacterium regains its active mode and causes 
the symptom
 [5]
. Secondary TB increases the chance of the infections spread 
to other organs such as kidneys, heart, and brain. 
3. Disseminated tuberculosis: means that the tuberculosis has infected the 
entire body system. It primarily affects the bones of spines, hips, joints and 
knees and even the central nervous system. It infects the CSF, the GIT, the 
adrenal gland, skin of the neck and even the heart
 [6]
. 
 
 
 
Figure 1 : Types of tuberculosis 
 
  
CELL WALL  
 The well-developed cell wall contains a considerable amount of a fatty 
acid, mycolic acid, covalent by attached to the underlying peptidoglycan bound 
polysaccharide arabinogalactan, providing an extraordinary lipid barrier. This 
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barrier is responsible for many of the medically challenging physiological 
characteristics of tuberculosis. The composition and quality of the cell wall 
components affect the bacteria’s virulence and growth rate.  
 
 The peptidoglycan polymer confers cell wall rigidity and just external to 
the bacterial cell membrane, another contributor to the permeability barrier of 
mycobacteria.  
 
 Another important component of the cell wall is lipoarabinomannan, a 
carbohydrate structural antigen on the outside of the organism that is 
immunogenic and facilitates the survival of mycobacteria within macrophages.  
 
 
 
Figure 2 : Mycobacterial cell wall 
  
 The cell wall is key to the survival of mycobacteria, and a more complete 
understanding of the biosynthetic pathways and gene functions and the development 
of antibiotics to prevent formation of the cell wall are areas of great interest
 [8]
. 
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MECHANISM: 
 The followings are the stages in TB 
[6-8]
. 
  
Stage 1: Droplets of nuclei are generated by during talking, coughing and 
sneezing. The droplets are inhaled. One droplet of nuclei contains more than 
3 bacilli. The infection begins 7-21 days. 
 
Stage 2: In the lungs, M. tuberculosis is taken up by alveolar macrophages, 
but they are unable to digest the bacterium. Its cell wall prevents the fusion 
of the phagosomes with a lysosome. MTB multiplies virtually unrestricted 
within unactivated macrophages until the macrophages burst.  
 
 
Figure 3 : Pathogenesis of Tuberculosis 
 
Stage 3:  The next stage, lymphocytes begin to infiltrate. T- Cells recognize 
processed and presented MTB antigen in context of Major 
Histocompatibility Complex molecules. This results in T- cell activation and 
the liberation of cytokines including gamma interferon (INF).  
               
Dendritic Cell 
(innate response) 
T cell 
Macrophage 
 
 
Granuloma  
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The liberation of INF causes in the activation of macrophages. These 
activated macrophages are capable of destroying MTB. At this stage, the 
individual becomes tuberculin- positive. 
Stage 4: Many activated macrophages can be found surrounding the 
tubercles. MTB uses these macrophages to replicate, and hence the tubercle 
grows. 
 
 The growing tubercle may invade a bronchus. If this happens, MTB infection 
can spread to other parts of the lung. Similarly, the tubercle may invade an artery or 
other blood supply line. The hematogenous spread of MTB result in extrapulmonary 
tuberculosis otherwise known as military tuberculosis
 [8]
.  
    
DIAGNOSIS
[9,10]
 : 
 Diagnosing active tuberculosis based merely on signs and symptoms is 
difficult, as is diagnosing the disease in those who are immunosuppressed. A 
diagnosis of TB should, however, be considered in those with signs of lung disease 
or constitutional symptoms lasting longer than two weeks
 [14]
.  
 
 A chest X-ray and multiple sputum cultures for acid-fast bacilli are typically 
part of the initial evaluation.  
 Laic acid amplification tests and adenosine deaminase testing may allow 
rapid diagnosis of TB. These tests are not routinely recommended. 
 Mantoux tuberculin skin test is often used to screen people at high risk for 
TB. Those who have been previously immunized may have a false-positive 
test result.  
 Interferon gamma release assays (IGRAs), on a blood sample, are 
recommended in those who are positive to the Mantoux test. These are not 
affected by immunization or most environmental mycobacteria, so they 
generate fewer false-positive results. 
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PREVENTION : 
 Tuberculosis prevention and control efforts primarily rely on the 
vaccination of infants and the detection and appropriate treatment of active cases. 
The World Health Organization has achieved some success with improved treatment 
regimens, and a small decrease in case numbers. 
 
TREATMENT
[11,12]
: 
Vaccines : 
 The only available vaccine as of 2011 is Bacillus Calmette-Guérin (BCG). 
In children it decreases the risk of getting the infection by 20% and the risk of 
infection turning into disease by nearly 60%. It is the most widely used vaccine 
worldwide, with more than 90% of all children being vaccinated. The immunity it 
induces decreases after about ten years. A number of new vaccines are currently in 
development
 [15]
. 
 
Drugs in used TB treatment
[11]
 : 
First line drugs: Isoniazid (H), Rifampin(R), Pyrazinamide (Z), Ethambutol 
(E),         Streptomycin(S). 
Second line drugs: Thiacetazone, Paraaminosalicylicacid, Ethinonamide, 
Cycloserine,         Kanamycin, Amikacin, Capreomycin. 
 
Table 1: World Health Organization recommended treatment regimens
[14] 
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EPIDEMIOLOGY
[16]
: 
 In 2015, 6.1 million new TB cases were notified to national authorities and 
reported to WHO. Notified TB cases increased from 2013–2015, mostly due to a 
34% increase in notifications in India. In 2015, there were an estimated 10.4 million 
new (incident) TB cases worldwide, of which 5.9 million (56%) were among men, 
3.5 million (34%) among women and1.0 million (10%) among children. People 
living with HIV accounted for 1.2 million (11%) of all new TB cases.  
 
 The best estimate is that there were 1.4 million TB deaths In 2015, and an 
additional 0.4 million deaths resulting from TB disease among HIV-positive people. 
In terms of cases, the best estimates for 2015 are that there were 10.4 million new 
TB cases (including 1.2 million among HIV-positive people), of which 5.9 million 
were among men, 3.5 million among women and 1.0 million among children. 
Overall, 90% of cases were adults and 10% children, and the male: female ratio was 
1.6:1. 
 
 In the African Region where the burden of HIV associated TB is highest, 
81% of notified TB, patients had a documented HIV test result. The proportion of 
known HIV-positive TB patients on ART was above 90% in India, Kenya, Malawi, 
Mozambique, Namibia and Swaziland. 
 
NEED TO FOCUS ON TUBERCULOSIS DISEASE  
 Tuberculosis is a leading cause of death worldwide. The World Health 
Organization estimates that one-third of the world’s population is currently 
infected with  M.tuberculosis, and that 1.3 million deaths result from these 
infections each year. 
 
  In the year 2000-2016, there were around 10 to 15 million people with latent 
TB in the U.S & in 2007, 2.4 million cases were reported.  
 
 In the year 2015, approximately 560 thousand new cases per year and 740 
thousand new patients were infected by both MTB and HIV. 
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NEED FOR NOVEL ANTI-TUBERCULOSIS AGENTS  
 
 A number of once active anti-tuberculosis drugs have now became inactive 
due to the ever-increasing rise in drug resistant strains of tuberculosis.  
 
  The lack in patient compliance is because the current treatment regimen 
lasts 6-9 months. The length of the treatment period makes difficulty in 
killing off the latent and slow-growing bacteria. 
 
 The multi -drug resistant TB (MDR-TB) occurs only when drug-susceptible 
TB is improperly or incompletely treated. According to the World Health 
Organization (WHO), MDR-TB is defined as a resistance to two of the most 
effective first line TB agents: Rifampicin and isoniazid
[15]
.  
 
 When a strain of TB becomes resistance to any fluoroquinolone and at least 
one of the three second-line agents (Capreomycin, Kanamycin and 
Amikacin), it becomes described at extensively drug-resistant TB(XDR-TB)  
 
  Emergence of Multi-resistant (MDR) strains and high susceptibility of 
human immunodeficiency virus (HIV) infected persons to the disease forced 
the scientist to develop novel anti-tuberculosis agents
[18]
.  
 
  It is evident from these facts there is an ever-growing need to develop 
novel agents for the treatment of tuberculosis. These new agents should be 
potent, fast acting, have an excellent pharmacodynamics / pharmacokinetics 
(PK/PD) profile, have high therapeutic index, and preferably have a novel 
mechanism of action as to avoid cross resistance with other agents. 
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ENZYME PROFILE 
Glutamine Synthetase 1 
 Glutamine synthetase is an enzyme that plays an essential role in the 
metabolism of nitrogen by catalyzing the condensation of glutamate and ammonia to 
form glutamine
 [18]
. 
Glutamine synthetase (GS; EC 6.3.1.2, also known as γ-glutamyl: ammonia Ligase) 
has three metal ions in the active site between the two pockets, which are necessary 
for stability and catalytic activity
[22]
. 
  
 
Glutamate + ATP + NH3                          Glutamine + ADP + phosphate 
 
 
 
Figure 4 : Glutamine synthetase 1(3ZXR)
[21] 
 
Protein name       : Glutamine synthetase 1 
Classification       : Ligase  
Chains                           : A, B, C, D, E, F 
Total structure weight   : 332264.16 
Length                  : 486 
Gene name         : glnA1 glnA Rv2220 MTCY190.31 MTCY427.01 
Function                         : catalyzes the ATP dependent condensation        
between glutamate and ammonia, to give glutamine. 
 
 
 GS 1 
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 M. tuberculosis in fact possesses four GS homologues, of which only one, 
the product of the glnA1 gene is highly expressed and essential for the growth of the 
bacteria both in vitro and in vivo. In addition to its well-characterized role in 
bacterial nitrogen metabolism, MtGS plays an important role in cell wall 
biosynthesis, specifically via the production of a poly-L-glutamate-glutamine 
component found exclusively in pathogenic mycobacteria. 
 
  Extracellular MtGS may also affect pH modulation in phagosomes and 
consequently prevent phagosome-lysosome fusion. Numerous studies indicate that 
inhibition of MtGS is a feasible therapeutic strategy. The extracellular location of the 
bulk of the enzyme furthermore obviates problems associated with the uptake of 
compounds across the notoriously impermeable mycobacterial cell wall
 [21]
.  
  
MECHANISM :  
 GS catalyzes the ATP dependent condensation of glutamate with ammonia 
to yield glutamine. This mechanism takes place in two step: 
 The first step is the formation of the activated intermediate -glutamyl 
phosphate. The Mg
2+
 ion coordinates the -phosphate oxygen of ATP to allow 
phosphoryl transfer to the  carboxylate group of glutamate, yielding the 
intermediate (acyl phosphate). ADP and Pi do not dissociate until ammonia binds 
and glutamine is released. The presence of ADP causes a conformational shift in GS 
that stabilizes the γ-glutamyl phosphate moiety. 
 
 This is followed by a second step deprotonation of ammonium, which 
allows ammonia to attack the intermediate from its nearby site to form glutamine
[24]
.  
 The inhibition of GS secreted by M. tuberculosis is sufficient to halt the 
growth of the bacterium, suggesting that TB-GS might be a valid target for anti-
tuberculosis drug-design. The structure of TB-GS is currently being solved to aid in 
the design of novel inhibitors for this enzyme
 [25]
. 
 
 The development of new classes of anti-tuberculosis drugs and new drug 
targets is of global importance, since attacking the bacterium using multiple 
strategies provides the best means to prevent resistance.  
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DRUG DISCOVERY
[30]
 
 Medicinal chemistry is the science that deals with the discovery and design 
of new therapeutic chemicals and their development into useful medicines. 
Medicinal chemistry involves synthesis of new molecules, investigation of the 
relationships between the structure of synthetic compounds and their biological 
activities, elucidations of their interactions with receptors of various kinds, including 
enzymes and DNA, the determination of their absorption, transport and distribution 
properties and studies of the metabolic transformations of these chemicals into other 
chemicals and their excretion.  
 
 The drug discovery process involves  
 Designing 
 Synthesizing 
 Characterization  
 Evaluation of new chemical entities 
 Suitability for therapeutic use  
 
 It also includes study of existing drugs, their biological properties and their 
quantitative structural activity relationship (QSAR). 
 
DRUG DESIGN
[31]  
 Drug discovery process involves a rapid search for a small molecule often 
called as lead. Lead molecule is a chemical compound, which possess 
pharmacological or biological activity. Sources of lead compounds can come from 
natural sources, such as plants, animals, or fungi and also from synthetic chemical 
libraries.  
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Figure :5  DRUG DISCOVERY CYCLE 
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LEAD OPTIMIZATION
[30]
  
 Newly pharmacologically active moieties may have poor drug-likeness and 
may require lead optimization step. This step involves chemical modification of a 
lead in order to improve their potency, selectively towards binding site, 
pharmacokinetic parameters and reduced toxicity.  
 
COMPUTER AIDED DRUG DESIGN
[31]
: 
 The latest breakthroughs in computer-aided drug design, drug delivery 
systems, and enabling technologies. Computer Aided Drug Design (CADD) and 
Delivery Systems offers an in-depth discussion of the computer-assisted techniques 
used to discover, design, and optimize new, effective, and safe drugs.  
 
 Drug design, sometimes referred to as rational drug design or simply rational 
design, is the inventive process of finding new medications based on the knowledge 
of a biological target. The drug is most commonly an organic small molecule that 
activates or inhibits the function of a biomolecule such as a protein.  
 
 Drug design frequently but not necessarily relies on computer modeling 
techniques. This type of modeling is often referred to as computer-aided drug 
design. Finally, drug design that relies on the knowledge of the three-dimensional 
structure of the biomolecular target is known as structure-based drug design.  
 
 Furthermore, in vitro experiments complemented with computation methods 
are increasingly used in early drug discovery to select compounds with more 
favorable (absorption, distribution, metabolism, and excretion) and toxicological 
profiles. 
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BASIC NUCLEUS CHOOSEN FOR STUDY
[33]
: 
 Benzothiazole is a heterocyclic compound, weak base, having varied 
biological activities and still of great scientific interest now a days.  
 
N
S
 
Figure 6 : General structure of benzothiazole 
 The Benzothiazole ring system bears phenyl ring fused with thiazole ring. 
Thiazole is a five membered heterocyclic ring system having sulfur and nitrogen as 
heteroatom. Benzothiazole is a privileged bicyclic ring system. 
 Benzothiazoles are an important class of privileged organic compounds of 
medicinal significance due to their recognized biological and therapeutic activities. 
Benzothiazole moites are part of compounds showing numerous biological activities 
such as  
 Antimicrobial  
 Anticancer  
 Anthelmintic 
 Anti-Diabetic 
 Anticonvulsant 
 Analgesic and Anti-Inflammatory Activities. 
 
  Due to its potent and significant biological activities, it has great 
pharmaceutical importance; hence, synthesis of derivatives is considerable interest. 
The small and simple benzothiazole nucleus if present in compounds involved in 
research aimed at evaluating new products that possess interesting biological 
activities
 [29]
. 
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REVIEW OF LITERATURE 
 
On the basis of the design, benzothiazole has been identified as potential Anti-
tubercular scaffold. It was therefore decided to conduct a literature survey of 
benzothiazole moieties and of the target glutamine synthetase  
I. Reviews related to the target- Glutamine synthetase  
1. D.Eisenberg et al. (2000)[22] carried out the glutamine synthetase as a 
regulated enzyme at the core of nitrogen metabolism, review the structural 
and functional studies of both bacterial and eukaryotic glutamine synthetase, 
with emphasis on enzymatic inhibitors. 
2. Marcus A. Horwitz et al. (2003)[23] assessed the role of glutamine 
synthetase (GS), in the pathogenicity of mycobacterium tuberculosis; glnA1 
was constructed via allelic exchange. The mutant had no detectable GS 
protein or GS activity and was auxotrophic for L-glutamine. In addition, the 
mutant was attenuated for intracellular growth in human THP-1 
macrophages. Based on growth rates of the mutant in the presence of various 
concentrations of L-glutamine the importance of the enzyme was known. 
These studies demonstrate that glnA1 is essential for M.tuberculosis 
virulence. 
3. Wojciech W. Krajewski et al.(2008)[24] summarized that glutamine 
synthetase catalyzes the ligation of glutamate and ammonia to form 
glutamine, with the hydrolysis of ATP. The enzyme is a central component 
of bacterial nitrogen metabolism and is a potential drug target. This study 
provides the first reported structure for a tauto form of the tuberculosis 
enzyme. The phospho compound, generated in situ by an active enzyme, 
mimics the phosphorylated tetrahedral adduct at the transition state.  
 
4. Berlicki L; Kafarski et al. (2008)[25] studied the Glutamine synthetase 
enzyme which catalyses the formation of glutamine from glutamate and 
ammonium ion. It is one of the most important enzymes in nitrogen 
metabolism. The first part of the review presents the long-dating research on 
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inhibitors of glutamine synthetase. Analysis of their structure activity 
relationship is presented in some detail. The second part of the paper is 
dedicated to potential medical applications of glutamine synthetase 
inhibitors, which is proved to be effective anti-tuberculosis agent with high 
selectivity towards the pathogen. 
 
5. Mats Larhed et al. (2009)[26] synthesized some potential anti-tubercular 
agents which targeted Glutamine Synthetase (GS), which is one of the latest 
targets of M.tb which catalyses the formation of glutamine from glutamic 
acid. In this work, novel GS inhibitors and new Palladium - catalyzed 
methods have been developed.  
 
6. Johan Gising et al. (2012)[27] identified several classes of MtGS inhibitors 
targeting the ATP-binding site by a recent high-throughput screening study . 
They explored one of these classes, the 2-tert-butyl-4,5-diarylimidazoles, and 
presented the design, synthesis, and X-ray crystallographic studies leading to 
the identification of MtGS inhibitors at submicromolar IC50 values and 
promising antituberculosis MIC values.  
  
7. Luke R. Odell et al. (2014)[28] presented an overview of the various 
strategies and compounds utilized to inhibit glutamine synthetase, a 
promising target for the development of anti TB drugs. The currently 
described inhibitors can be divided into two main classes, those that target 
the glutamate-binding site and ATP-competitive inhibitors. Compounds 
belonging to the first class are typically low molecular weight and polar 
analogues of glutamate, methionine sulfoximine or phosphinothricin. 
 
II. Review related to benzothiazole nucleus and its biological activities   
8. P Vicini et al. (2006)[36]  synthesized new 2-thiazolylimino-5-arylidene-4-
thiazolidinones, unsubstituted or carrying hydroxy, methoxy, nitro and 
chloro groups on the benzene ring. They were assayed in vitro for their 
antimicrobial activity against Gram positive and Gram negative bacteria, 
yeasts and mould. The compounds were found to be very  
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potent towards all the tested Gram positive microorganisms (MIC ranging 
from 0.03 to 6 lg/mL in most of the cases) and Gram negative Haemophilus 
influenzae (MIC 0.15–1.5 lg/ mL), whereas they were ineffective against 
Gram negative Escherichia coli and fungi up to the concentration of 
100g/ml. 
N
S
NH
S
O
N
R
 
9. J P Sen & S D Srivastava et al. (2008) [37] carried out the systemic 
investigation of synthesis and biologically active compounds of 2 amino 
benzothiazole. Several new [(5-arylidine -2 aryl 4- oxo- 1,3-thiazolidine) 3-
imino acetyl] 2 amino benzothiazole from 2 amino benzothiazole have been 
synthesized. All the synthesized products were evaluated for their 
antibacterial activity. 
N
S
NH
O
NH N
S
O
Ar
Ar  
  
 
10. Khalid A.Al Badraani et al. (2008)[38]  stated substituted anilines are 
readily converted to 2-amino substituted benzothiazole by reaction with 
Potassium thiocynate and bromine in glacial acetic acid. The product 4-nitro-
2-amino benzothiazole Acetyl chloride was allowed to react with various 
aryl amine to give aryl aminoacetyl -2-amino-4-nitrobenzothiazole 
derivatives. The reaction of hydrazine hydrate and ethyl -3-amino beridyl 
acetate gave the  acid hydrizide. The synthesized compounds were 
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characterized on the basis of IR spectral analysis and the results found 
compatible with their assigned structures. 
N
S
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O
NH R
N
+
O
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11. SR Reddy et al. (2010)[39] described the synthesis of benzothiazole appended  
β-lactams. This methodology involves [2+2]-cycloaddition of benzothiazole 
substituted imines with chloroacetyl chloride in the presence of triethylamine 
to yield the corresponding product (substituted azetidine 2 one derivatives )in 
moderate to good yields. The reaction is compatible with a wide varity of 
functional groups. 
 
N
S
N
O
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12. Taleb H. Al-Tel et al. (2011)[40] studied new antimicrobial agents, 
imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole Results from 
this study showed that the nature of the substituents on the armed aryl groups 
determines the extent of the activity of the fused imidazopyridine and/or 
imidazobenzothiazole derivatives. Preliminary structure activity observations 
revealed that bromofluoro substituents enhanced the antimicrobial activity 
significantly compared to other substituents. 
 
13. Pareek et al. (2014)[43] synthesized the substituted-2-aryl-3-(benzothiazolyl)-
1,3-thiazolidine-4-one. The synthesized compounds were screened for their 
anti-inflammatory, antiulcer, antitumor, entomological and antibacterial 
activities. 
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14. Loah R. Hemeda et al. (2015)[44] have reviewed the synthesis and different 
biological activities of some derivatives of 5-arylidene derivatives of 
benzothiazol-2-yl substituted 2- imino thiazolidin-4-ones and N-Mannich 
bases of N-substituted-2-Iminothiazolidin-4-ones.  
N
S N
S
NH
O
Ar
                               
N
S
N
S
N
O
CH3  
 
 
15. Khaled R.A.Abdellatif et al. (2015)[45] synthesised new 5-arylidene 
thiazolidinone derivatives and evaluated for their potential as antitumor lead 
compounds. These compounds were tested in vitro on human breast MCF-7 
and non-small cell lung A549 cancer cell lines which showed potent 
antitumor activity in the micro molar level. All the prepared compounds 
were docked against EGFR using 4-anilinoquinazoline inhibitor (PDB ID: 
IM17) in away to explore their binding mode. 
 
Ar = (a)-2-thionyl ;(b)-  3-(OCH3)C6H5  
NR1R
2 
N
S
O
O
CH3
N
NH
S
NH
Ar
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III. Review of the several works on benzothiazole, few of them are enlisted 
here in support of their antitubercular activity 
16. A.A.Chowki et al. (2008)[46] synthesized various 6-nitro-2-[4-formyl-3-
(substituted phenyl) pyrazol-1-yl] benzothiazole and screened them for 
antitubercular activity against H37Rv strain of Mycobacterium tuberculosis. 
Synthesis of 6-Nitro-2-[4-formyl-3-(substituted phenyl) pyrazol-1-yl] 
benzothiazoles reported in this study provides a novel example of Vilsmeier 
Haack reagent mediated heterocyclic synthesis. 6-Nitro-2-[4-formyl-3-
(substituted phenyl) pyrazol-1-yl] Benzothiazoles exhibit a range of activities 
in the antitubercular screens. Many of these derivatives exhibited activity 
comparable to that of the standards. 
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17. B.S. Sathe et al. (2010)[47] treated 4-Fluoro-3-chloroanilline with Potassium 
thiocyanate in presence of Glacial acetic acid and bromine to synthesise 2-
amino-6-fluoro-7-chlorobenzothiazole. The synthesized compound in 
presence of m-nitro benzaldehyde refluxed in ethanol gave 3-[6'-fluoro-7'-
chloro(1',3') benzothiazol-2'-yl]-m-nitrophenyl(1,3) thiazolidine-4-one. This 
compound was treated with ortho, meta and para nitroanillines, ortho, meta, 
para chloroanillines, morpholino, Piperazine and diphenylamine in the 
presence of DMF to obtain different derivatives. Some of these derivatives 
showed promising antimycobacterial activity. 
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18. Chakraborti et al.(2014)[48] reported  that benzothiazole-2-carboxyaryl alkyl 
ssamides as new class of potent anti-mycobacterial agents. Forty one target 
compounds have been synthesized following a green synthetic strategy using 
water as the reaction medium to construct the benzothiazole scaffold 
followed by microwave-assisted catalyst-free, and ammonium chloride-
catalysed solvent-free amide coupling. The antimycobacterial potency of 
these compounds were determined against H37Rv strain. Twelve compounds 
exhibited promising anti-TB activity in the range of 0.78-6.25 μg/mL and 
were found to be non-toxic(<50% inhibition at 50g/ml) to HEK 20 293T 
cell lines with therapeutic index of 8-64. 
 
19. H Chikhalia et al. (2014)[49] synthesized and studied a series of 
quinazolinone based 5-arylidine-2-(2-methyl-4-oxoquinazlin-3-(4H)-yl) 
ethyl) amino) thiazol-4 (5H)-one derivatives. Quinazoline and styryl 
thiazolidinones have been clubbed through ethyl linkage to get hybrid 
molecules. The final synthesized compounds were screened for their in vitro 
antimicrobial activity against bacterial fungal strains. In vitro 
antimycobacterial efficacy has also been studied against Mycobacterium 
tuberculosis H37Rv using BACTEC MGIT method.  
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20. Vinayak  et al. (2015)[50] reacted 2-Amino-4/6-substitutedbenzothiazoles on 
reaction with substituted aromatic aldehydes which gave 2-(arylidenimino)-
4/6-substituted benzothiazoles , which on reaction with mercaptoacetic acid 
provide 2-aryl-3-(substituted benzothiazolyl)-1,3-thiazolidine-4-ones. All the 
newly synthesized compounds were screened for antibacterial activity at a 
concentration of 200 μg/mL and 100 μg/mL using DMF as a control and 
Streptomycin and Ceftazidime used as standard against gram positive and 
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gram negative bacteria. 
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Y = N(C2H5)2 ; 4-methyl piperidin-1-yl 
 
IV. Reviews related to the synthetic procedure: 
             Scheme 1: 
21. Robert J. Alaimo (1973)[51] explained the synthesis of the 4H-
pyrimmido[2,1-b]benzothiazole-4-ones(4). It involves the reaction of 
suitability substituted 2aminobenzothiazoles(1) with 
alkoxymethylenemalonatee esters(2). When the initial condensation was 
carried out in alcohol, the product was the corresponding 2-(benzothiazolyl) 
aminomethylene malonate(3),(5). These intermediates were readily cyclized 
to the corresponding pyrimido[2,1-b]benzothiaoles in hot Dowtherm A. 
However since the complete reaction could be accomplished more 
conveniently in one step by heating a mixture of (1) and (2) in Dowtherm A 
until the theoretical amount of alcohol has been collected, the compounds(4)  
were prepared by this method. 
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22. Saeed Balalaie et al. (2012)[52] carried out one-pot three-component reaction 
of 2-aminobenzothiazole, benzaldehyde derivatives and β-ketoester, β-
diketone or malonate derivatives in solvent-free conditions, to yielded 
pyrimido[2,1-b]benzothiazole derivatives at 60°C in 60% - 72% yields 
without using any catalyst. 
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23. P K Sahu et al. (2014)[53]  developed an efficient method for the preparation 
of 4H-pyrimido [2,1-b]benzothiazole derivatives by the condensation of 
aldehydes,  β-keto ester, and 2-amino benzothiazole under solvent and 
solvent free conditions using various catalysts. Good yield was obtained at 
60-65
0
C under solvent-free conditions. This study suggests that acetic acid 
and metal catalysts follow different mechanism.  
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Scheme 2: 
24. Khalid A.Al Badraani et al. (2008)[38] connected substituted anilines to 2-
amino substituted benzothiazole by reaction with Potassium thiocynate and 
bromine in glacial acetic acid. The -4-nitro-2-amino benzothiazole acetyl 
chloride obtained from reaction between -4-nitro-2-amino benzothiazole with 
chloro acetyl chloride. 
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25. BS Holla et al. (2008)[54] synthesized the series of novel 4-aryl/chloroalkyl-
2-(2,3,5-trichlorophenyl)-1,3-thiazoles by condensing 2,3,5-
trichlorobenzenecarbothioamide with phenacyl bromide/ dichloroacetone. 
2,3,5-Trichlorobenzaldehyde thiosemicarbazone on treatment with phenacyl 
bromide afforded 4-aryl-2-(2,3,5-trichlorophenylidenehydrazino)-1,3-
thiazoles (10aeg) in good yield. These compounds were also screened for 
their antibacterial and antifungal activities.  
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26. Haider Behbehani et al. (2011)[55] The 4-thiazolidinones were used as key 
intermediates for the synthesis of 2-arylimino-5-arylidene-4-thiazolidinones 
derivatives via nucleophilic addition reactions with the arylidene 
malononitrile. The 4-thiazolidinone reacted with the benzenediazonium 
chloride to afford the arylhydrazones. 
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27. Navin B Patel and Sarvil D. Patel et al. (2012)[56] synthesized 2-
Chloromethyl-5- substituted phenyl-1,3,4-oxadiazoles then coupled with 
phenolic group of 4-hydroxy aniline, further converted to 2-chloro-N-
substituted phenyl acetamides on reaction with chloro acetyl chloride and 
finally cyclized with ammonium thiocynate to form targeted compounds. 
 
28. Dhamak Kiran Bhausaheb et al. (2015)[57] synthesized the derivatives of 
benzothiazoles and evaluated for their antifungal activity. 2-amino 
benzothiazole was first converted to 6 substituted derivatives of 2-amino 
benzothiazole by nitration and bromination reaction to yield 6-nitro-2-amino 
benzothiazole and 6-bromo-2-aminobenzothiazole respectively. All the 
derivatives including 2-amino benzothiazole were further treated with 
chloroacetyl chloride to form chloroacetamido derivatives of benzothiazole. 
Further, the product was treated with various heterocyclic and aromatic 
amines. Synthesized substituted benzothiazole derivatives were investigated 
for their antifungal activity. 
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R
2-chloro-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide
6-methyl-1,3-benzothiazol-2-amine
ClCOCH2Cl
Ethanol, -HCl
 
 
V. Reviews related to biological evaluation of Antitubercular activity by 
MABA 
 
29. Collins and Franzblau et al.  (1997) In response to the need for rapid, 
inexpensive, high-throughput assays for antimycobacterial drug screening, a 
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microplate-based assay which uses Alamar blue reagent for determination of 
growth was evaluated. They concluded  MABA is sensitive, rapid and 
nonradiometric and offers the potential for screening, with or without 
analytical instrumentation, large numbers of antimicrobial compounds 
against slow-growing mycobacteria. 
30. Robin K Pettit et al. (2005) explained about the redox indicator Alamar blue 
has been used extensively in planktonic bacterial and fungal susceptibility 
assays and mammalian cell culture cytotoxicity assays. Alamar blue is 
reduced by FMNH2, FADH2, NADH, NADPH, and cytochromes. Alamar 
blue both fluoresces and changes color in response to chemical reduction, 
and the extent of the conversion is a reflection of cell viability. Alamar blue 
is water soluble, so cell proliferation assays are not required. Data may be 
collected  with either fluorescence-based or absorbance-based instruments.  
 
31. Jose d Jesus Alba-Romero et al. (2011) applied the Alamar blue assay to 
determine the susceptibility to anti-tuberculosis pharmaceuticals. The results 
showed that the MABA test is fast and easy to apply. It is very reliable 
method to determining the drug susceptibility to pharmaceuticals.  
 
 
32. Sephra N.Ramprasad et al. (2012) studied the various applications of 
Alamar blue as an indicator. Alamar blue is an indicator that is used to 
evaluates metabolic function and cellular health. The Alamar blue bioassay is 
being utilized to access cell viability and cytotoxicity in a biological and 
environmental system and in a number of cell types including bacteria, yeast, 
fungi, and protozoa.  
 
33. Franck Bonnier et al. (2015) indicated the  comparisons of 2D and 3D cell 
culture models differences in cellular morphology and metabolism, 
commonly attributed the better representation of invivo conditions of the 
latter cell culture environment. Using the well established Alamar Blue 
assay, the study demonstrates how the transfer from 2D substrates to 3D 
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collagen matrices can affect the uptake of the resazurin itself, affecting the 
outcome of the assay. Using flow cytometry, it is demonstrated that the cell 
viability is unaffected when cells are grown on collagen matrices. 
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AIM AND OBJECTIVES 
 
AIM:  
 The aim of this project is to design molecules into potential anti-tubercular 
activity that is capable of inhibiting cell wall synthesis by inhibiting glutamine 
synthetase. The designed compounds will be synthesized, characterized and 
evaluated for activity and toxicity.  
 
OBJECTIVE: 
 
 To design the molecule and docked against a specific crucial target, 
Glutamine Synthetase I, which is involved in the cell wall biosynthesis and 
nitrogen metabolism.  
 In-silico prediction of Drug Likeness and Toxicity 
 Laboratory synthesis of the top G score compounds 
 Melting point determination and Thin layer Chromatography 
 Characterization of the synthesized compounds by 
o Infrared Spectroscopy 
o Nuclear Magnetic Resonance Spectroscopy 
o Mass Spectroscopy 
 Determination of in vitro anti tubercular activity of synthesized compounds  
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The present study will be conducted according to the following design 
    
 
 
 
 
  
  
 
 
 
               
 
    
 
 
 
 
 
   
 
 
 
  
 
   
 
 
 
 
 
 
Identification of Basic Nucleus 
Docking the Molecule against the Target Protein 
Top Score Compound Selected 
Optimization of the Highly Interacting Molecule 
Synthesis 
 Toxicological Assessment 
In-Vitro Anti Tubercular Activity by  
MABA 
Structural Modification of Basic Nucleus  
 
Characterization 
Spectroscopy- 
IR,NMR,MAS
S 
Insilco Investigation of Drug Likeness 
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PLAN OF WORK  
 The main aim of this project is to synthesize a novel compounds containing 
anti tubercular activity. 
 The toxicity of compounds are visualized by OSIRIS®. 
 The selected enzyme is docking against compounds which is to be 
synthesized. 
 The selected compounds were synthesized at appropriate manner then 
purified by recrystallization, characterized by sharp melting point and Thin 
Layer Chromatography.  
 The following compounds are confirmed by characterized techniques which 
is hyphenated like, GC-MS and LC-MS analysis(if necessary).In this 
technique, molecular weight and purity of the formed compounds are 
determined.  
 The molecular structure of the compounds is interpreted by proton NMR 
(1HNMR) and the functional groups of the compounds are analyzed by IR 
studies. 
 The anti-tubercular activity of the compounds are evaluated by MABA  
 
 Finally, a novel and potent anti-tubercular activity containing compounds are 
synthesized, purified, characterized and evaluated. 
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MATERIALS AND METHODS 
 
4.1 COMPUTER AIDED DRUG DESIGN 
[66]
  
 A binding interaction between a small molecule ligand and an enzyme 
protein results in activation or inhibition of the enzyme, which results in agonism or 
antagonism.  
 Identification of new ligands for a given receptor by searching large 
databases of 3D structures of small molecules to find those fitting the binding pocket 
of the receptor using docking programs. This method is known as virtual screening. 
 
DOCKING  
 
 Docking program is used to fit the ligand molecule into the target structure in 
a variety of position, conformations and orientations. Docking mode is known as 
pose. Each pose scored based on its complementarities to the target in terms of shape 
and properties such as electrostatics in order to identify the most favorable energetic 
pose.  
 
SCORING FUNCTIONS
[67]
  
 One early general-purposed empirical scoring function to describe the 
binding energy of ligands to receptors was developed by Böhm. This empirical 
scoring function took the form:  
 ΔG0 – empirically derived that in part corresponds to the overall loss 
of translational and rotational entropy of the ligand upon binding. 
 ΔGhb – contribution from hydrogen bonding  
 ΔGionic – contribution from ionic interactions  
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 ΔGlip – contribution from lipophilic interactions where is surface area 
of lipophilic contact between the ligand and receptor  
 ΔGrot – entropy penalty due to freezing a rotatable bond in the ligand 
bond upon binding  
                                          ΔGbind   = -RT ln Kd 
                                             Kd    =                         Kd     = 
ΔGbind = ΔG desolvation + ΔG motion + ΔG configuration + ΔG interaction 
Where:  
 ΔG desolvation  is the enthalpic penalty for removing the ligand from solvent  
 
 ΔG motion  is the entropic penalty for reducing the degrees of freedom when a 
ligand binds to its receptor  
 
 ΔG configuration is the conformational strain energy required to put the ligand 
in its "active" conformation  
 
 ΔG interaction  is the enthalpic gain for "resolvating" the ligand with its 
receptor  
 
 According to Gibbs free energy equation, the relation between dissociation 
equilibrium constant, Kd, and the components of free energy was built.  
 
 
 
 
 
 
 
[Ligand] [Receptor] 
     [Complex] 
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Molecular Docking by AUTODOCK
® [74,75] 
 AutoDock
®
 4.2.5.1 is an automated procedure for predicting the interaction 
of ligands with biomacromolecular targets. Progress in biomolecular x-ray 
crystallography continues to provide important protein and nucleic acid structures. 
These structures could be targets for bioactive agents in the control of animal and 
plant diseases, or simply key to the understanding of fundamental aspects of 
biology. The precise interaction of such agents or candidate molecules with their 
targets is important in the drug discovery process.  
 
 In any docking scheme, two conflicting requirements must be balanced: the 
desire for a robust and accurate procedure, and the desire to keep the computational 
demands at a reasonable level. The ideal procedure would find the global minimum 
in the interaction energy between the substrate and the target protein and exploring 
all available degrees of freedom (DOF) for the system. AutoDock
®
 combines two 
methods to achieve these goals: rapid grid-based energy evaluation and efficient 
search of torsional freedom.  
 
 The current version of AutoDock
®  
using the Lamarckian Genetic Algorithm 
and empirical free energy scoring function, typically will provide reproducible 
docking results for ligands with approximately 10 flexible bonds. 
 
 The quality of any docking results depends on the starting structure of both 
the protein and the potential ligand. The protein and ligand structure need to be 
prepared to achieve the best docking results. 
 
 Protein preparation  
 Ligand preparation  
 Receptor grid generation  
 Ligand docking (screening) 
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DOCKING PROCEDURE 
Preparation of protein: 
 
 
 
Preparation of Ligand: 
 
 
 
 
 
 
 
Grid preparation:  
 
 
 
 
 
 
 
 
 
 Grid – Macromolecule -open (open the pdb file thet has been saved and 
then save it in pdbqt extension in AutoDock folder) 
 Grid – Set map types –open ligand : tools to define the atom types for 
the grids that will be calculated 
 Grid – Grid box – launches interactive commands for setting the grid 
dimensions and center (Set dimension of 60 x 60 x 60 – Center: center 
on macromolecule) 
 File – Close saving current 
 Grid – Output – save as .gpf  (grid parameter file) 
 Open command prompt [ cd AutoDock 
                                         cd 4.2.5.1 
                                         autogrid4.exe –p a.gpf –l a.glg] 
 
 Ligand –Input from file  
 Ligand – Torsion –choose torsion: Rotatable bonds are shown in green, 
and non-rotatable bonds are shown in red. Bonds that are potentially 
rotatable but treated as rigid, such as amide bonds and bonds that are 
made rigid by the user, are shown in magenta.  
 Ligand – Torsion –set number of torsion: sets the number of rotatable 
bonds in the ligand by leaving the specified number of bonds as 
rotatable. 
 Ligand – Output – save as .pdbqt  in AutoDock folder  
 
 Read molecule from the file (allows reading of PDB coordinate files.) 
 Edit -Charges – Compute Gasteiger  (for arbitrary molecules) 
 Edit – Hydrogen –Merge non polar 
 Save as .pdb in  AutoDock
® 
folder 
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Preparation of Docking Parameters: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visualization / Interpretation of Docking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Docking –Open the macromolecules – set rigid file name. 
 Docking – ligand – open the ligand. 
 Docking –search parameters – genetic algorithm parameters  : this 
command opens a panel for setting the parameters used by each of the 
search algorithms, such as temperature schedules in simulated 
annealing and mutation/crossover rates in genetic algorithms. 
 Docking – docking parameters: opens a panel for setting the 
parameters used during the docking calculation, including options for 
the random number generator, options for the force field, step sizes 
taken when generating new conformations, and output options. 
 Docking- output –Lamarkian GA –save as .dpf  (docking parameter 
file) 
 Open command prompt [autodock4.exe –p a.dpf –l a.dlg] 
 
 Analysis –Docking – open .dlg (docking log file) file 
 Analysis – open the macromolecule 
 Analysis – Confirmation –Play and Play ranked by energy :  Play- will 
use the order of conformations as they were found in the docking 
calculations, and Play Ranked By Energy will order the conformations 
from lowest energy to highest energy. 
 Analysis – Load : Information on the predicted interaction energy is 
shown at the top and the individual conformations 
 Analysis – Docking – show interaction: specialized visualization to 
highlight interactions between the docked conformation of the ligand 
and the receptor. 
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LIPINSKI’S RULE[68] 
 
 Lipinski’s rule of five is a rule of thumb to evaluate drug likeness, ie., to 
determine if a chemical compound with a certain pharmacological or biological 
activity has the properties that would make it a likely orally active drug in humans. 
Christopher A. Lipinski formulated the rule in 1997, based on the observation that 
most medication drugs are relatively small and lipophilic molecules.  
 The rule describes molecular properties important for a drug’s 
pharmacokinetics in the human body, including their absorption, distribution, 
metabolism and excretion (ADME). However, the rule does not predict if a 
compound is pharmacologically active.  
 The rule is important for the drug development where a pharmacologically 
active lead structure is optimized step-wise for increased activity and selectivity, as 
well as drug-like properties as described by Lipinski’s rule. The modification of the 
molecular structure often leads to drugs with higher molecular weight, more rings, 
more rotatable bonds, and a higher lipophilicity. Lipinski’s rule says that, an orally 
active drug has no more than one violation of the following criteria:  
 
 Partition coefficient of log P less than 5 
 Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with 
one or more hydrogen atoms) 
 Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
 Molecular weight under 500 daltons  
 An additional rule was proposed by Veber 
< 10 rotatable bonds 
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IN-SILICO TOXICITY PREDICTION
[73] 
OSIRIS
®
 : 
 In silico toxicity prediction is done using OSIRIS
®
 Property Explorer. It is a 
free software available for access in the Organic Chemistry Portal. Using this 
prediction tool, mutagenicity, tumerogenicity, skin irritation and reproductive effects 
can be calculated.  
 The prediction properties relies on a precompiled set of structure fragment 
that gives rises to toxicity alerts in case they are encountered in the structure 
currently drawn. These fragment lists is created by rigorously shredding all 
compounds in the data base known to be active in a certain toxicity class. During the 
shredding any molecule is first cut at every rotatable bonds leading to a set of core 
fragments. 
 
MOLINSPIRATION
®
 : 
 The designed and docked molecules are screened in silico using 
MOLINSPIRATION
®
 Cheminformatics software to evaluate drug likeness. This 
tool is quick and easy to use. It is a software available online for calculation of 
important molecular properties log P, polar surface area, number of hydrogen bond 
donors and acceptors and others, as well as prediction of bioavailability score for the 
most important drug targets (GPCR ligands, Kinase inhibitors, ion channel 
modulators, nuclear receptors). 
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4.2 SYNTHETIC METHODOLOGY 
 
Scheme 1: 
 General Procedure for the Synthesis of 4H-Pyrimido [2, 1-b] benzothiazole 
derivatives: 
 A mixture of 2-aminobenzothiazole (0.01mol) and aromatic aldehyde 
derivatives (0.01mol) and β keto ester (0.01mol) were heated at 60°C in the solvent-
free conditions for 5 - 6 hr. Completion of the reaction was confirmed by TLC 
(Petroleum ether: EtOAc 1:4). At the end of the reaction, the mixture was washed 3 
times (3 × 20 ml) with water and diethyl ether.  
 
Scheme 2: 
 General Procedure for the Synthesis of Imino-3-(6-
substitutedbenzo[d]thiazol-2-yl) thiazolidin-4-one: 
 2 amino benzothiazole (0.01mol) and chloroacetyl chloride (0.01mol) in dry 
benzene (50ml) in the presence of potassium carbonate (0.15mol) was refluxed for 
12 hours. The mixture was stirred with water (100 mL) and filtered. The solid 
product was then washed with 5% NaHCO3 solution and subsequently with water. 
The crude product was dried and crystallized from ethanol. Then the product of the 
first (0.01mol) was added to ammonium thiocynate (0.03mol) in ethanol (30ml) and 
heated under reflux for 5 hours at 120
0
C and then kept overnight. Then the sample 
was collected then washed with water and recrystallized the product with ethanol.  
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REACTANT PROFILE 
2 Amino Benzothiazole: 
N
S
NH2
 
1, 3-benzothiazol-2-amine 
 
SYNONYM                                           1, 3-benzothiazol-2-amine 
MOLECULAR FORMULA                    C7H6N2S 
MOLECULAR WEIGHT                       150.20 
MELTING POINT                                  126-129
0
C                                         
DESCRIPTION                               Pale white colour powder 
 
Diethyl Malonate: 
O O
O O
CH3CH3  
Diethyl malonate 
 
SYNONYM                                            1,3-Diethyl propanedioate 
MOLECULAR FORMULA                    C7H12O4  
MOLECULAR WEIGHT                        160.16 
BOILING POINT                                    199
0
C 
DESCRIPTION                                       Colourless liquid  
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Acetyl acetone: 
CH3 CH3
O O
pentane-2,4-dione
 
SYNONYM               Pentane-2, 4-dione  
MOLECULAR FORMULA                  C5H8O2 
MOLECULAR WEIGHT                      100.12 
BOILING POINT                                  140
0
C 
DESCRIPTION                            Reddish brown colour liquid 
Chloro Acetyl Chloride: 
chloroacetyl chloride
O
Cl
Cl
 
SYNONYM                Chloroacetyl chloride 
MOLECULAR FORMULA                   C2H2Cl2O 
MOLECULAR WEIGHT                       112.192 
BOILING POINT                                   140
0
C 
DESCRIPTION                             Colourless liquid 
 
Ammonium thiocynate: 
MOLECULAR FORMULA                    NH4SCN 
MOLECULAR WEIGHT                        76.122 
BOILING POINT                                    170
0
C 
DESCRIPTION                               Colourless hygroscopic crystalline solid 
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Salicylaldehyde: 
 
 
 
MOLECULAR FORMULA                  C7H6O2 
MOLECULAR WEIGHT                     122.121 
BOILING POINT                                 196-197
0
C 
DESCRIPTION                           Colourless liquid 
 
4 –OH Benzaldehyde:  
OH
O
4-hydroxybenzaldehyde
 
 
MOLECULAR FORMULA                    C7H6O2 
MOLECULAR WEIGHT                        122.121 
BOILING POINT                                    112-116
0
C 
DESCRIPTION                              White powder 
 
O
OH
salicylaldehyde
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SYNTHETIC DERIVATIVES: 
A. 4H-pyrimido[2,1-b][1,3]benzothiazole derivatives 
B. 5-Arylidene-2-imino-3-(benzo[d]thiazol-2-yl) thiazolidine-4- one 
 
Reaction: 1 
 
CHO
+
X Y
OO
+
N
S
NH2
N
S
N
N
S
N
O
Y
Solvent free 
R
1,3-benzothiazol-2-amin
e
-XOH
R R
Decarboxylation
Oxidation
4-phenyl-2H-pyrimido[2,1-b][1,3
]benzothiazole
1-(4-phenyl-4H-pyrimido[2,1-b][1,
3]benzothiazol-3-yl)ethanone
keto esterBenzaldehyde
i)
ii)
5-6 hrs
 
 
 
 
 
 
β- 
60
0
C 
Y- OC2H5; CH3 
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Reaction: 2 
Synthesis of 5-Arylidene-2-imino-3-(benzo[d]thiazol-2-yl) thiazolidin-4-one 
derivative 
Cl
ClO
chloroacetyl chloride
+
N
S
NH2
R
1,3-benzothiazol-2-amine
N
S
NH
ClO
N-1,3-benzothiazol-2-yl-2-chloroacetamide
N
S
N
S
O
NH
R
3-(1,3-benzothiazol-2-yl)-2-imino-1,3-thiazolidin-4-one
Dry benzene
12 hrs
Reflux
6 hrs
NH
4
SCN in Ethanol
 
 
 
 
120
0
C 
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SYNTHETIC REACTION 
COMPOUND NAME: AH  
 
N
S
NH2
OH
CHO
+ + CH3 CH3
OO
OH
N
S
N
O
CH3
CH3
1-[4-(4-hydroxyphenyl)-2-methyl-4H-
pyrimido[2,1-b][1,3]benzothiazol-3-yl]
ethanone
pentane-2,4-dione4-hydroxybenz
aldehyde
1,3-benzothiazol-
2-amine
6 hrs
 
 
 
COMPOUND NAME: DAA  
 
N
S
NH2
CHO
OH
+ +
CH3 CH3
OO
N
S
N
OH
pentane-2,4-dione1,3-benzothiazol-2
-amine
6 hrs
2-(4H-pyrimido[2,1-b][1,3]
benzothiazol-4-yl)phenol
salicylaldehyde
 
 
 
COMPOUND NAME: DAS 
 
N
S
NH2 +
CHO
OH
4-5 hrs
N
S
N
OH
1,3-benzothiazol-2-amine 2-[(E)-(1,3-benzothiazol-2-ylimino)
methyl]phenol
salicylaldehyde
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COMPOUND NAME: DAC 
 
N
S
NH2
N
+
O
-
O
+ +
H5C2O OC2H5
OO
5-6 hrs
OH
CHO
OH
N
S
N
N
+
O
-
O
OC2H5
O
6-nitro-1,3-benzothiaz
ol-2-amine
4-hydroxyben
zaldehyde
diethyl 
malonate
ethyl 
4-(4-hydroxyphenyl)-8-nitro-4H-pyrimido
[2,1-b][1,3]benzothiazole-3-carboxylate
 
 
 
COMPOUND NAME: KS 
 
 
N
S
NH2
N
+
O
-
O
+
Cl
Cl
O N
S
NH Cl
O
N
+
O
-
O
O
N
S
N
S
NH
N
+
O
-
O
5 hrs
reflux
Dry benzene
NH4SCN in Ethanol
12 hrs
2-chloro-N-(6-nitro-1,3-benzothiazol-2
-yl)acetamide
2-imino-3-(6-nitro-1,3-benzothiazol-2-yl)-
1,3-thiazolidin-4-one
6-nitro-1,3-benzothiazol-
2-amine
chloroacetyl 
chloride
 
 
 
 
120
0
C 
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4.3 METHODS OF CHARACTERISATION 
 The synthesized compounds were identified by using the following methods.  
Melting Point  
 The melting points of the compounds were determined by the capillary tube 
method.  
Thin Layer Chromatography
 [77]
  
 Pre-coated TLC plates with silica gel GF 250 were used. Samples of 
reactants and products were prepared with suitable solvents. Solvent system was 
prepared based on the nature of the compounds.  
Stationary phase   : Pre coated gel plate (silica gel GF 250) 
Mobile phase         : Ethyl acetate: Hexane (4:6) ; Pet ether : Ethyl acetate (1:4) 
Visualizing agent  : Iodine chamber. 
 The determination of the Rf value of the reactants and the final product was 
done.  
 The characterization was carried out using sophisticated methods like 
Infrared spectroscopy, Nuclear magnetic resonance spectroscopy and Mass 
spectroscopy. 
 
Infra Red Absorption Spectroscopy
[78] 
 IR (region 2.5-15) is a powerful tool for identifying the pure organic and 
inorganic compounds, with the exception of a few homo nuclear molecules such as 
O2, N2, Cl2 all the molecular species absorb infrared radiation. 
 Instrument          : FT-IR spectrophotometer (model no: 3000) 
Sample technique: KBr Pellet technique.  
 
Materials and Methods 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 47 
 
NMR Spectroscopy
 [80]
 
 Nuclear magnetic resonance involves the interaction between oscillating 
magnetic field of electromagnetic radiation and the magnetic energy of the hydrogen 
nucleus or some other type of nuclei when these are placed in an external static 
magnetic field.  
 NMR enables us to study the number of equivalent protons and their 
electronic environment. It reveals the different chemical environment in which the 
proton is present and helps us to ascertain the structure of molecule.  
 The number of signals in an NMR spectrum denotes the number of the set of 
equivalent protons in a molecule. The position of the signals in the spectrum helps 
us to know the nature of protons such as aromatic, aliphatic, acetylenic, vinyl, 
adjacent to some electron attracting or electron-releasing group etc.  
Instrument used  : BRUKER Advance 500 NMR spectrometer  
Solvent                : Deuterated Dimethyl Sulphoxide 
Internal standard : Tetramethylsilane(TMS). 
  
Mass Spectroscopy
[77,80]
  
 Mass spectroscopy is an analytical technique used to establish the molecular 
weight and help in the determination molecular structure of the analyte under 
investigation. In this technique, the compound under investigation is bombarded 
with a beam of electrons producing ionic fragments of the original species. The 
relative abundance of the fragment ion formed depends on the stability of the ion 
and of the lost radical. The resulting charged particles are then separated according 
to their masses. Each kind of ion has a particular ratio of mass to charge, i.e. m/z 
ratio (value). Mass spectrum is a record of information regarding various masses 
produced and their relative abundances.  
 LC-MS: Liquid chromatography with mass spectroscopy is used to 
characterize the non-volatile compounds but GC-MS is used to characterize only the 
volatile compounds. 
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 Q-Tof-Mass Spectroscopy (Q-Tof micro hybrid quadrupole Time of flight 
mass spectrometer) with electro spray ionization and in JEOL GCMATE II GC-MS. 
 
4.4 BIOLOGICAL EVALUATION  
 The designed and synthesized molecules need to be screened for their 
activity to inhibit the growth of the Mycobacterium tuberculosis.  
ANTITUBERCULAR ACTIVITY
[86]
  
 The following methods are generally used for in vitro studies for the 
evaluation of anti-tubercular activity.  
 Resazurin Micro plate Assay (REMA)  
 Nitrate Reductase Assay (NRA)  
 Micro plate Alamar Blue Assay (MABA)  
 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)  
 Middle Brook 7H11 Agar dilution Assay  
 Broth Micro dilution Method  
 BACTEC system  
 Luciferase Reporter Phage Assay  
 The synthesized compounds may be evaluated for anti-tubercular activity 
using any of the above methods. In this technique, Microplate Alamar Blue Assay is 
used to evaluate the anti-tubercular activity. It is an easy and economic method. 
 
 
 
Materials and Methods 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 49 
 
MICROPLATE ALAMAR BLUE ASSAY 
[88] 
 Alamar blue dye is used as an indicator for the determination of viable cells.  
 The oxidized form, Resazurine (also called as diazo-resorcinol, azoresorcin, 
resazoin and resazurine) is non- toxic, non-fluorescent and blue in colour which 
becomes pink and fluorescent upon reduction to resorufin by viable cells.  
 Growth is measured qualitatively by a visual colour change and the amount 
of fluorescence produced is proportional to the number of the living cells, which is 
determined by colorimetric, and fluorimetric methods.  
Advantages  
 High sensitivity  
 Does not require cell lysis  
 Works well with different types of cells  
 Safe and economical  
 Results are linear and quantitative  
 Water soluble 
 Not required cell proliferation assays 
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Assay Procedure For Estimating Anti-Tb Activity Using
[89]
  
 The anti-mycobacterial activity of compounds is assessed against M. 
tuberculosis using Alamar Blue micro plate assay (MABA).  
 This methodology is non-toxic, uses a thermally stable reagent and shows 
good correlation with proportional and BACTEC radiometric method.  
 Briefly, 200 micro litter of sterile de-ionized water is added to all outer 
perimeter wells of sterile 96 wells plate to minimize evaporation of medium 
in the test wells during incubation. 
 The 96 wells plate receives 100 micro litter of the middle brook 7H9 broth 
and serial dilution of compounds is made directly on plate.  
 The final drug concentrations tested are 100 to 0.2 micro gram/ml.  
 Plates are covered and sealed with paraffin and incubated at 370C for five 
days.  
 After this time, 25 micro litters of freshly prepared 1:1 mixture of Alamar 
blue reagent and 10% tween 80 is added to the plate and incubated for 24 
hrs.  
 A blue colour in the well is interpreted as no bacterial growth, and pink 
colour was scored as growth.  
 The MIC is defined as lowest drug concentration, which prevents the colour 
change from blue to pink.  
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RESULT AND DISCUSSION 
5.1     INSILICO SCREENING OF DRUG LIKENESS 
 MOLINSPIRATION
®
 Cheminformatics software used to evaluate drug likeness. 
 
Sample code : AH 
 
 
 
 
 
Sample code : DAA 
 
 
 
 
 
 
 
Sample code : DAC 
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                 The Lipinski’s Rule of Five describes molecular properties important for 
a drug’s pharmacokinetics in the human body, including their absorption, 
distribution, metabolism and excretion (ADME). 
 
                 These 5 compound shows no violations and obey the Lipinski’s Rule of 
Five that is confirmed by using MOLINSPIRATION
®
 Cheminformatics software. 
The above 5 scaffolds were used for the synthesis and for further studies. 
 
  
 
 
 
 
 
 
 
  Sample code : DAS 
 
Sample code : KS 
 
Figure 7: Calculation of Molecular Properties and Biological Activities 
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DOCKING 
 The derivatives of the selected 5 scaffolds were docked against Glutamine 
Synthetase 1(3ZXR -Mtb enzyme). The molecules were screened for good docking 
score and interactions by using Autodock
®
 software. 
Table 2: The molecules with good docking score were mentioned as below: 
 
Code 
name 
Structures 
Docking 
score 
Kcal/mol 
Docking view 
AH 
OH
N
S
N
CH3
O
CH3
 
 
-7.51 
 
DAA N
S
N
OH
 
 
-7.77 
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Code 
name 
Structures 
Docking 
score  
Kcal/mol 
Docking view 
 
DAC 
OH
N
S
N
O
O
CH3
N
+
O
OH
 
-8.45 
 
DAS N
S
N
OH
 
-6.67 
 
KS 
N
S
N
S
O
NH
 
-6.41 
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Fig 8: Interaction View Of AH 
  
 
 
Fig 9: Docking View Of AH 
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Fig 10: Interaction View of DAA 
Green colour bond indicates the Hydrogen bond interaction 
 
 
 
Fig 11: Docking View of DAA 
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Fig 12: Interaction View of DAC 
Green colour bond indicates the hydrogen bond interaction 
 
 
 
Fig 13: Docking View of DAC 
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Fig 14: Interaction View of DAS 
Green colour bond indicates the hydrogen bond interaction 
 
 
 
 
Fig 15: Docking View of DAS 
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Fig 16: Interaction View of KS 
Green colour bond indicates the hydrogen bond interaction 
 
 
 
Fig 17: Docking View of KS 
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Table 3: Interaction with Amino acids 
Name Structure 
Docking 
score 
Interaction with amino 
acid 
AH 
 
-7.51 
ASN 325,ARG 59, GLY 
374, GLU 459,ILE 
31,LYS 455,MET 263, 
PHE -262,454, SER- 
372,373, PRO -29,264 
THR 323, VAL 324. 
DAA 
 
-7.71 
H- bond: ARG 24, TYR 
247; 
GLN 243, GLY 30, ILE 
31, MET 32, LEU 244, 
LYS- 246, 250, TYR 247. 
DAC 
 
-8.45 
H-bond: LYS 246, LYS 
250, TYR 259; 
MET 263, PHE 262, SER 
372, TYR- 153,261. 
DAS 
 
-6.67 
H- bond: GLY 374, PRO 
29, SER 373;ARG 59, 
GLY 30, ILE 31, LYS 
246, MET 263, PHE 262. 
KS 
 
-6.41 
ARG 24, ASN 251, GLN 
243, HIS 34, GLY 30, ILE 
31, LYS 246, MET 32, 
TYR 247. 
Pyrazinamide 
 
-4.41 
H-bond: ARG 24; 
ARG 79, ASN -24, 90, 92, 
GLN 243, LEU 244, MET 
32, THR 77, TYR 247. 
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IN-SILICO TOXICITY PREDICTION 
 
 Insilico toxicity prediction was done for the filtered 5 compounds using 
OSIRIS
® 
Property Explorer. This software is available for access in the Organic 
Chemistry Portal. Using the prediction tool, mutagenicity, tumorogenicity, skin 
irritation and reproductive effects were calculated. The results were colour-coded. 
The green colour represents that the compounds are non-toxic. Yellow color 
indicates moderate and red colour indicates severe toxicity of the chemicals 
respectively. 
 
  
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure 18: Toxicity Prediction of AH 
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Figure 19: Toxicity Prediction of DAA
n of  AH 
 Toxicity Prediction of  AH 
 
 
 
 
 
 
 
 
 
Figure 20: Toxicity Prediction of DAC 
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              The selected 5 compounds are non toxic which was confirmed by the 
Osiris® property explorer software. 
 
 
Figure 21: Toxicity Prediction of DAS 
Figure 22: Toxicity Prediction of KS 
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5.2    PRODUCT PROFILE 
 The selected 5 scaffolds were synthesized in an appropriate manner and 
recrystallized. The synthesized compounds were evaluated for their purity through 
melting point determination and checking for absence of parent compounds or other 
new compounds by TLC. 
The Rf value of parent compounds 
 2 amino benzothiazole  - 0.75 
 Salicyaldehyde                - 0.54        
             4-OH benzaldehyde        - 0.59 
 
Table 4: The synthesized compounds were evaluated by the following: 
S.No 
CODE 
NAME 
MOLECULAR 
WEIGHT 
YIELD % MELTING 
POINT 
Rf  
VALUE 
1.  AH 336.4 67% 198-2000C 0.68 
2.  DAA 280.3 59% 115-1170C 0.85 
3.  DAC 400.4 74% 198-2000C 0.68 
4.  DAS 254.3 69% 118-1200C 0.86 
5.  KS 249.3 70% 198-2000C 0.63 
 
 The Rf value of the synthesized compounds was varied from the Rf value of 
the reactants. It is concluded that the reaction was completed. The compounds were 
obtained in acceptable yield. The melting point range confirmed the purity of the 
product. 
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Code: AH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OH
N
S
N
O
CH3
CH3
 
 
Methyl4-(4-hydroxyphenyl)-2-methyl-2H-
pyrimido[2,1b][1,3]benzothiazole-3-carboxylate 
 
Molecular formula            C19H16N2O3S 
Molecular weight              336.41 
Appearance                        Dark green colour 
Melting point                     198-200
0
C 
Composition                      C(67.84%), H(4.79%), N(8.33%), 
                                          O(9.51%), S(9.53%) 
Molar refractivity             96.06 ±0.5 cm
3 
Molar volume                    247.1 ±7.0 cm
3 
Surface tension                  53.4 ±7.0 dyne/cm 
Density                              1.36 ±0.1 g/cm
3 
Parachor                             668.4 ±8.0 cm
3 
Index of refraction            1.704 ±0.05          
Polarizabilty                        38.08 ±0.5 10
-24
 cm
3
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Code: DAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OH
N
S
N
 
2-(2H-pyrimido [2,1-b][1,3]benzothiazol-4-yl)phenol 
 
Molecular formula            C16H12N2OS 
Molecular weight              280.345 
Appearance                       Dark green 
Melting point                    115-117
0
C 
Composition                     C (68.55%), H (4.31%), N(9.99%), 
                                         O (5.71%), S (11.44%) 
Molar refractivity             81.75 ±0.5 cm
3 
Molar volume                   203.4 ±7.0 cm
3 
Surface tension                 58.2 ±7.0 dyne/cm 
Density                             1.37 ±0.1 g/cm
3 
Parachor                            561.9 ±8.0 cm
3 
Index of refraction            1.736 ±0.05          
Polarizabilty                       32.41 ±0.5 10
-24
 cm
3 
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Code: DAC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OH
N
S
N
O
O
CH3
N
+
O
-
O  
Ethyl 4-(4-hydroxyphenyl)-8-nitro-2H-pyrimido [2, 1-b][1,3]benzothiazole-3-
carboxylate 
 
Molecular formula C19H18N3O5S 
Molecular weight   400.429 
Appearance            Yellow  
Melting point       198-200
0
C 
Composition          C(56.99%), H(4.53%), N(10.49%), 
  O(19.98%), S(8.01%) 
Molar refractivity 103.30 ±0.5 cm
3 
Molar volume      259.8 ±7.0 cm
3 
Surface tension    66.0 ±7.0 dyne/cm 
Density               1.52 ±0.1 g/cm
3 
Parachor               740.5 ±8.0 cm
3 
Index of refraction 1.726 ±0.05          
Polarizabilty                       40.95 ±0.5 10
-24
 cm
3 
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Code: DAS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
S
N
OH
 
2-[(Z)-(1,3-benzothiazol-2-ylimino)methyl]phenol 
 
Molecular formula          C14H10N2OS 
Molecular weigh               254.308 
Appearance                       Pale yellow  
Melting point                   118-120 
0
C 
Composition                     C (66.12%), H(3.96%), N(11.02%), 
  O (6.29%), S (12.61%) 
Molar refractivity             74.18 ±0.5 cm
3 
Molar volume                   193.6 ±7.0 cm
3 
Surface tension                54.0 ±7.0 dyne/cm 
Density                             1.31 ±0.1 g/cm
3 
Parachor                            525.1 ±8.0 cm
3 
Index of refractio             1.691 ±0.05          
Polarizabilty                      29.41 ±0.5 10
-24
 cm
3 
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Code: KS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
N
S
N
S
NH  
3-(1,3-benzothiazol-2-yl)-2-imino-1,3-thiazolidin-4-one 
 
Molecular formula        C10H7N3OS2 
Molecular weight          249.314 
Appearance                   Pale yellow  
Melting point                 198-200
0
C 
Composition                  C (48.17%), H (2.83%),N(16.85%), 
                                                O (6.42%), S (25.72%) 
Molar refractivity                    66.37 ±0.5 cm
3 
Molar volume                146.6 ±7.0 cm
3 
Surface tension              82.3 ±7.0 dyne/cm 
Density                          1.69 ±0.1 g/cm
3 
Parachor                        441.7 ±8.0 cm
3 
Index of refraction                   1.865 ±0.05          
Polarizabilty                  26.31 ±0.5 10
-24
 cm
3 
 
Results and Discussion 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 70 
 
5.3 CHARACTERIZATION 
Infrared Spectroscopy 
 The samples were prepared by the KBr pellet techniques and the samples are 
analyzed by FT-IR technique.  
Sample code: AH  
.
 
IR spectrum of AH 
 
Table 5: IR Interpretation of AH 
S.NO WAVE NUMBER TYPES OF VIBRATIONS FUNCTIONAL GROUP 
1.  3440 cm-1 OH Stretching Aromatic OH groups 
2.  2923 cm-1 CH Stretching Alkyl group 
3.  1735 cm-1 C=O Stretching Ketone group 
4.  1488 cm-1 C=N bending 
Heteroaromatic 
compound(in Ring) 
5.  1242 cm-1 NH bending Secondary amino group 
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Sample Code: DAA 
 
 
IR spectrum of DAA 
 
 
Table 6: IR Interpretation of DAA 
S.No WAVE NUMBER TYPES OF VIBRATIONS FUNCTIONAL GROUP 
1.  3433 cm-1 OH – Stretching Aromatic OH Groups 
2.  2923 cm-1 CH-  Stretching Alkyl Group 
3.  2352 cm-1 NH -Stretching Secondary Amino Group 
4.  1643 cm-1 C=C Stretching Aromatic Ring 
5.  1450 cm-1 C=N Bending 
Heteroaromatic 
Compound(In Ring) 
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Sample code: DAC 
 
IR spectrum of DAC 
 
 
Table 7: IR Interpretation of DAC 
S.No WAVE NUMBER TYPES OF VIBRATION FUNCTIONAL GROUPS 
1.  3440 cm-1 OH– Stretching Aromatic OH Groups 
2.  2854 cm-1 CH-  Stretching Alkyl Group 
3.  2322 cm-1 NH -Stretching Secondary Amino Group 
4.  1728 cm-1 C=O Stretching Aliphatic Ester Group 
5.  1512 cm-1 NO2 Stretching Aromatic Nitro Group 
6.  1450 cm-1 C=N Bending 
Heteroaromatic 
Compound(In Ring) 
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Sample code: DAS 
 
 
IR spectrum of DAS 
 
 
Table 8: IR Interpretation of DAS 
S.No WAVE NUMBER TYPES OF VIBRATION FUNCTIONAL GROUP 
1.  3409 cm-1 OH– Stretching Aromatic OH Group 
2.  3062 cm-1 CH-  Stretching Aromatic Group 
3.  2368 cm-1 C=C -Stretching Aromatic Ring 
4.  1450 cm-1 C=N Stretching 
Heteroaromatic 
Compound 2(In Ring) 
5.  1319 cm-1 C=N Stretching Aliphatic Amino Group 
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Sample code: KS 
 
IR spectrum of KS 
 
 
Table 9: IR Interpretation of KS 
S.No WAVE NUMBER TYPES OF VIBRATION FUNCTIONAL GROUP 
1.  3170 cm-1 CH Stretching Aromatic Group 
2.  2067 cm-1 NH Stretching Amino Group 
3.  1650 cm-1 C=O-Stretching Ketone Group 
4.  1573cm-1 C=C Stretching Aromatic Ring 
5.  1407 cm-1 C=N Stretching 
Heteroaromatic 
Compound(In Ring) 
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Table 10: Determination of Functional Group by IR Spectra 
Absorption  Band AH DAA DAC DAS KS 
CH Stretching      
NH Stretching      
C=O Stretching      
C=N Stretching      
OH Stretching      
NH2 Stretching      
NO2 Stretching      
 
             
          The IR spectrum will be used to identify the functional group of the 
synthesized compound. It also shows the absence of the functional group peaks of 
the parent compounds and the presence of the new functional group peaks of the 
synthesized compounds.  
           The presence of new functional group region: 
C=N stretching in the region of 1300-1600cm
-1 
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NMR SPECTROSCOPY 
Sample Code: AH  
 
1
H NMR Spectrum of AH 
 
 
Table 11: 
1
H NMR Interpretation of AH 
S.NO  VALUE TYPES OF PEAK NUMBER OF PROTONS 
1.  9.9-10.1 Singlet 1 
2.  6.7-8 Multiplet 4 
3.  2.9 Singlet 1 
4.  2.5-2.6 Doublet 2 
5.  1.1-1.3 Multiplet 4 
 
OH
N
S
N
O
CH3
CH3
 
  C19H16N2O3S 
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Sample Code : DAA 
 
 
1
H NMR Spectrum of DAA 
 
 
 
Table 12: 
1
H NMR Interpretation of DAA 
S.NO  VALUE TYPES OF PEAK NUMBER OF PROTONS 
1.  7.9-8.0 Doublet 1 
2.  7.7-7.8 Doublet 2 
3.  7.1-7.5 Multiplet 7 
4.  4.1 Singlet 2 
 
OH
N
S
N
 
  
C16H12N2OS 
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Sample code : DAC  
 
 
1
H NMR Spectrum of DAC 
 
 
 
Table 13: 
1
H NMR Interpretation of DAC 
S.NO  VALUE TYPES OF PEAK NUMBER OF PROTONS 
1.  7.9-8.1 Multiplet 4 
2.  7.1-7.8 Multiplet 8 
3.  6.9-7.0 Multiplet 3 
4.  6.5 Singlet 1 
5.  2.2-2.4 Doublet 2 
 
OH
N
S
N
O
O
CH3
N
+
O
-
O  
          C19H18N3O5S 
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Sample code : DAS 
 
 
1
H NMR Spectrum of DAS 
 
 
Table 14: 
1
H NMR Interpretation of DAS 
S.NO  VALUE TYPES OF PEAK NUMBER OF PROTONS 
1.  12.1 Singlet 1 
2.  9.2 Doublet 1 
3.  7.8-8.0 Multiplet 2 
4.  6.9-7.8 Multiplet 4 
5.  6.2-6.4 Singlet 1 
6.  2.5-2.6 Triplet 1 
 
 
N
S
N
OH
 
       C14H10N2OS 
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Sample code:  KS 
 
  
Table 15: 
1
H
 
NMR Interpretation of KS 
S.NO  VALUE TYPES OF PEAK NUMBER OF PROTONS 
1.  7.0-7.1 Multiplet 1 
2.  7.1-7.3 Triplet 1 
3.  7.3-7.4 Doublet 1 
4.  7.4-7.5 Singlet 2 
5.  7.6-7.7 Triplet 1 
  
             The 
1
H NMR Spectral data of all the synthesized compounds were used to 
assign molecular structure. A short sharp singlet was observed at 4.5-6.5(ppm) for 
all compounds, which might be due to the presence of NH proton. All the 
compounds showed multiplet signals for the presence of aromatic protons between 
6.4-8.0(ppm) and Heteroaromatic protons between 5.5-6.5(ppm). The singlet peak 
was observed at 8.5-12 (ppm) for AH, DAA, DAC and DAS compounds , due to the 
presence of OH proton. 
O
N
S
N
S
NH  
C10H7N3OS2 
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MASS SPECTROSCOPY 
Sample Code: AH 
 
 
LC –MS Spectrum of AH 
 
 
OH
N
S
N
O
CH3
CH3
 
MW: 336.41 
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Sample Code: DAA 
 
 
 
LC –MS Spectrum of DAA 
 
 
OH
N
S
N
 
MW: 280.34 
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Sample code: DAC 
 
 
 
LC –MS Spectrum of DAC 
 
OH
N
S
N
O
O
CH3
N
+
O
-
O  
           C19H18N3O5S 
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Sample code: DAS 
 
 
 
LC –MS Spectrum of DAS 
 
N
S
N
OH
 
              C14H10N2OS 
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Sample code: KS 
 
 
 
GC –MS Spectrum of KS 
 
O
N
S
N
S
NH
 
MW: 249.31 
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Table 16: Molecular Weight Determination by Mass Spectra 
 
S.No SAMPLE NAME ACTUAL MASS CALCULATED MASS 
1.  AH 336.41 337.17 
2.  DAA 280.34 279.29 
3.  DAC 400.42 401.36 
4.  DAS 254.31 254.26 
5.  KS 249.31 249.15 
 
 
            All the synthesized compounds exhibited molecular ion peak (M±1) of 
varying intensities established the molecular weight of the compounds. It was 
observed that the compounds (AH, DAA, DAS, DAC) have fragment ions at m/z 
value of 83.36 and KS have fragment ions at m/z value of 175.1which probably 
due to the following structures. 
N
N
4,5-dihydropyrimidine
        
N
S
N S
2-(1,3-thiazolidin-3-yl)-4,5-dihydro-1,3-thiazole
 
                          m/z : 82.05                                                 m/z :174.10 
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IN-VITRO ANTITUBERCULAR ACTIVITY 
                  Compounds were screened for invitro anti tubercular activity (0.8-
100g/ml) by Microplate Alamar Blue Assay. The organism H37Rv used in the 
study i.e. Mycobacterium tuberculosis. The anti mycobacterial activity of the 
compounds was assessed against M.tuberculosis using Microplate Alamar Blue 
Assay (MABA).  
 All the synthesized compounds showed anti-mycobacterial activity in 
varying degrees against the organism tested. 
  The organism tested was susceptible to all the synthesized compounds and 
the minimum inhibitory concentration for the compounds varied between 
12.5 and 6.25g/ml.  
 The data pertaining to these observations are presented in the table.  
 Inhibition was compared using Pyrazinamide- 3.125 g/ml, Ciprofloxacin-
6.25g/ml and streptomycin- 6.25g/ml as standard. 
 
Table 17: Biological Evaluation of the Synthesized Compounds 
S.No Sample 
100 
g/ml 
50 
g/ml 
25  
g/ml 
12.5 
g/ml 
6.25 
g/ml 
3.12  
g/ml 
1.6 
g/ml 
0.8 
g/ml 
1. AH S S S R R R R R 
2. DAA S S S S R R R R 
3. DAC S S S S S R R R 
4. DAS S S S S R R R R 
5. KS S S S S R R R R 
R – RESISTANT; S – SENSITIVE 
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Figure 23: Standard Drug Photograph 
Strain used: M.tuberculosis (H37RV strain): ATCC No- 27294 
Pyrazinamide – 3.125g/ml; Streptomycin – 6.25 g/ml; 
Ciprofloxacin – 3.125 g/ml 
 
NAM
E 
100 
g/ml 
50 
g/ml 
25 
g/ml 
12. 
5g/ml 
6.25 
g/ml 
3.12 
g/ml 
1.6 
g/ml 
0.8 
g/ml 
DAA 
 
AH 
DAS 
DAC 
KS 
DNS 
 
Figure 24: Biological Evaluation of Synthesized Compounds 
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Figure 25 : MABA assay 
 
COMPARATIVE STUDY OF SYNTHESIZIED COMPOUNDS WITH 
FIRST LINE ANTI-TB DRUG 
Table 18: Comparative Study with Standard Drug 
NAME 
MOLECULAR 
WEIGHT 
g/mol 
DOCKING 
SCORE 
Kcal/mol 
MABA 
ASSAY 
(MIC) 
g/ml 
PYRAZINAMIDE(Z) 123.11 -4.41 3.125 
AH 336.41 -7.51 25 
DAA 280.34 -7.77 12.5 
DAC 400.42 -8.45 6.25 
DAS 254.31 -6.67 12.5 
KS 249.31 -6.41 12.5 
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The biological evaluation of the compounds found that they were sensitive at 
12.5-6.25g /ml to the specific organism and shows less activity to the standard 
drugs. The synthesized compounds have the better docking score than Pyrazinamide. 
This is the way indicates the limitation of docking software.  
 
Table 19: Molecules docked against different targets 
 
Name of the 
Enzyme 
Docking Scores Kcal/mol 
AH DAA DAC DAS KS 
Glutamine 
Synthetase 1 
-7.5 -7.7 -8.4 -6.6 -6.4 
Decaprenylphosporyl 
β-d-Ribose 2-
Epimerase 
-6.8 -7.6 -6.6 -7.6 -5.5 
Cyclopropane 
Mycolic Acid 
Synthase 2 
-7.0 -5.9 -6.5 -7.9 -4.4 
Methoxy Mycolic 
acid Synthetase 2 
-5.1 -6.4 -7.3 -6.8 -7.7 
 
 
 It is concluded that the synthesized compounds have best docking score 
around 6.5-8.5 Kcal/mol against Glutamine synthetase 1, which is more important in 
the cell wall synthesis of the Mycobacterium tuberculosis. Also they have related 
docking score against various target. sTherefore, the compounds are capable of 
inhibiting Decaprenylphosporyl β-d-Ribose 2-Epimerase, Cyclopropane Mycolic 
Acid Synthase 2 and Methoxy Mycolic acid Synthetase 2. 
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SUMMARY 
 Glutamine synthetase 1, critical enzyme for the cell wall synthesis of 
Mycobacterium tuberculosis was chosen after the review of literature.  
 A database of 100 molecules with high probability of inhibiting the target 
Glutamine Synthetase was chosen by making changes to a known inhibitor 
scaffold that is aryl substituted benzothiazole nucleus was chosen for the 
study. 
 In silico drug likeness properties were determined by using Molinspiration® 
Cheminformatics
 software based on the Lipinski’s Rule of Five. 
 Docking of the 3D structures of these 100 entities against the 3D structure of 
Glutamine Synthetase gave an insight about the energetic (molecular 
docking) by using AUTODOCK
®
 4.2.5.1 software. 
 Of these 100 structures, only 5 structures which showed minimum binding 
energy were chosen for synthesis (around -6.6 to -8.0 kcal/mol). 
 They exhibited the better docking score than the standard Anti-TB drugs like 
Pyrazinamide -4.41kcal/mol by using AUTODOCK
®
 Software. 
 Toxicity risk assessment prediction was done for all the 5 compounds by 
OSIRIS
®
 property explorer which is available online. The results are colour 
coded as green colour, which predict the drug likeness. 
 The purity of the synthesized compounds were confirmed by TLC and 
melting point and then characterized by IR, 
1
H NMR, GC-MS and LC-MS. 
 The pure compounds were screened for in vitro Antitubercular activity by 
Microplate Alamar Blue Assay method. 
 The synthesized compounds showed sensitivity (Minimum Inhibitory 
Concentration) in the range 12.5-6.25g/ml. The standard drugs 
Summary 
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Pyrazinamide, Ciprofloxacin and Streptomycin exhibited antimycobacterial 
activity at 3.125g/ml, 3.125g/ml and 6.25g/ml concentration 
respectively. This indicates that the synthesized compounds are as active as 
the standard drugs. 
 The synthesized compounds showed better docking score than Pyrazinamide. 
However, all of them are less active than Pyrazinamide.  
 The synthesized compounds have related docking score around 6.5-8.2 
Kcal/mol against various target. Therefore, they are capable of inhibiting 
Decaprenylphosporyl β-d-Ribose 2-Epimerase, Cyclopropane Mycolic Acid 
Synthase 2 and Methoxy Mycolic acid Synthetase 2, which is also had the 
functional importance in the Mycobacterium tuberculosis. 
 
CONCLUSION 
 
 It is concluded that the synthesized compounds might effectively inhibit the 
chosen target Glutamine Synthetase I which is essential for the Mycobacterial 
Tuberculosis. Further structural modifications of the synthesized compounds will aid 
in the development of potential molecule against the tuberculosis pathogen. 
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